|
 |
Pravachol PravastatinThis page contains recent news articles, when available, and an overview of Pravachol Pravastatin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Crestor (rosuvastatin) is better than Pravachol (pravastatin) in reducing triglycerides and low-density lipoprotein (LDL) levels—“badâ€? cholesterol levels—in ... AIDSmeds.com HIV/AIDS Treatment News Competitors by Product Report - Jul 19, 2008 Healthcare. Biopharmaceuticals. Cardiovascular System. Vascular Disorders. Coronary Artery Disease (CAD). HMG CoA Reductase Inhibitors (Statins) ... $75.00 - Revere Reports - Revere Ranbaxy launches Pravastatin in US - Jun 26, 2007 New Delhi June 25 Two months after it finally received the go ahead from the US Food and Drug Administration, Ranbaxy has launched the 80 mg generic version ... Hindu Business Line STATINS' BENEFIT ONLY TO HEART ; CANCER-FIGHTING ABILITY … - Jan 4, 2006 One theory has been that statins reduce inflammation; another suggests that by stopping the formation of low-density lipoprotein (LDL) cholesterol, ... Pay-Per-View - Hartford Courant - ProQuest Archiver Article: Barr Pharmaceuticals and its subsidiary PLIVA announced that... - Jan 1, 2007 Barr Pharmaceuticals and its subsidiary PLIVA announced that PLIVA has received final approval from the FDA for its Abbreviated New Drug Application to ... Pay-Per-View - Medical Marketing & Media - HighBeam Research China One Corp acquires IND Lifetech Group Ltd - Dec 12, 2008 - Deal ... - Dec 12, 2008 CANADA - China One Corp acquired all the outstanding stock of IND Lifetech Group Ltd, a producer of milk. The transaction had been subject to customary ... Pay-Per-View - deals - Alacra Store Health Canada issues advisory over statins - Jul 14, 2005 OTTAWA — Some patients with underlying health conditions could be at risk of serious side-effects from widely prescribed cholesterol-lowering drugs known as ... CTV.ca Barr Pharmaceuticals and its subsidiary PLIVA announced that PLIVA... - Jan 1, 2007 Barr Pharmaceuticals and its subsidiary PLIVA announced that PLIVA has received final approval from the FDA for its Abbreviated New Drug Application to ... Free with registration - Medical Marketing & Media - AccessMyLibrary.com EBSCOhost Connection: Generic Pravastatin Approved. - Jul 1, 2006 FDA Consumer: The article reports on the approval of the first generic version of Bristol-Myers Squibb's Pravachol (pravastatin sodium) Tablets by the US ... Subscription - FDA Consumer - EBSCO Publishing Ranbaxy hopeful of launching cholesterol drug next year - Nov 3, 2005 RANBAXY Laboratories Ltd is hopeful of launching the 80 mg dosage form of Bristol-Myers Squibb's Pravachol (pravastatin) on a 180-day exclusive basis some ... Hindu Business Line GlaxoSmithKline PLC acquires Bristol-Myers Squibb Pakistan from... - Dec 22, 2008 PAKISTAN - GlaxoSmithKline PLC of the UK acquireD Bristol-Myers Squibb Pakistan (Pvt) Ltd, a Punjab-based pharmaceutical manufacturing firm, ... Pay-Per-View - deals - Alacra Store FDA Approves Generic Version Of Cholesterol Drug - Apr 25, 2006 By Mark Huffman. The Food and Drug Administration has approved the first generic version of Bristol-Myers Squibb's Pravachol, a move it touts as an ... Consumer Affairs Cholesterol drugs for kids debated - Jul 13, 2008 By Jung Eun Lee. Last week's recommendation by the American Academy of Pediatrics —- that some children as young as 8 with high cholesterol be prescribed ... Atlanta Journal Constitution Barr's subsidiary Pliva receives approval for Pravastatin Tablets 10... - Nov 28, 2006 Barr Pharmaceuticals Inc (Barr) and its subsidiary Pliva dd announced on 28 Nov 2006 that Pliva has received final approval from the US Food and Drug ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Cholesterol Drug Tied to Sleep Disturbances - Nov 7, 2007 By Amanda Gardner. "The study suggests that simvastatin [Zocor] is more likely to have sleep disruption," said Dr. Sidney Smith, past president of the ... HealthCentral.com Competitors by Product Report - Jul 19, 2008 Healthcare. Biopharmaceuticals. Cardiovascular System. Vascular Disorders. Coronary Artery Disease (CAD). HMG CoA Reductase Inhibitors (Statins) ... $75.00 - Revere - Alacra Store AHA: Fish Oil Plus Statin Reduces Coronary Events - Nov 17, 2005 By Peggy Peck, Senior Editor, MedPage Today. DALLAS, Nov. 17 - Fish oil supplements in high doses combined with statin therapy deliver a one-two punch that ... CNN FDA Approves First Generic Pravastatin - Apr 24, 2006 The Food and Drug Administration today approved the first generic version of Bristol-Myers Squibb's Pravachol (Pravastatin Sodium Tablets), an important ... Pay-Per-View - U.S. Food & Drug Administration Documents - Factiva, from Dow Jones Crestor Called Less Safe Than Other Statins - May 23, 2005 By Peggy Peck, Senior Editor, MedPage Today. BOSTON, May 23-A new analysis of post-marketing safety reports suggests that patients using Crestor ... MedPage Today Generic pravastatin approved.(Bristol-Myers Squibb Co.'s Pravachol … - Jul 1, 2006 The FDA has approved the first genetic version of Bristol-Myers Squibb's Pravachol (pravastatin sodium) Tablets, an important step in the agency's effort to ... $4.95 - FDA Consumer - ECNext HEALTH FOR LIFE The Power of Statins - Dec 6, 2008 A new study supports the effectiveness of a drug treatment, and prompts a Harvard cardiologist to change the way he practices medicine. ... Newsweek secondhand smoke Test scores ... | Article from The Washington Post |... - Jan 18, 2005 ...secondhand smoke Test scores ... ... find The Washington Post articles. secondhand smoke THE QUESTION Smoke from other people's cigarettes can cause health ... Pay-Per-View - Washington Post - HighBeam Research TAKE FIVE - Mar 4, 2007 CORRECTION: This story contains corrected material, published March 6, 2007. 5 Questions Your Pediatrician Wishes You'd Ask: ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Press Release: FDA approves first generic Pravastatin. - M2 Presswire... - Apr 25, 2006 FDA approves first generic Pravastatin. from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Article: Conflict concerns raised on FDA panels - The Record (Bergen ... - Sep 22, 2005 Conflict concerns raised on FDA panels ... find The Record (Bergen County, NJ) articles. The Associated Press The Record (Bergen County, NJ) 09-22-2005 ... Pay-Per-View - The Record - HighBeam Research 'Rattray wrong on cholesterol drugs' - Mar 23, 2007 In The Gleaner of Monday, March 19, Dr. Garth Rattray takes me to task for my advice to readers on the dangers of using the popular cholesterol-lowering ... Jamaica Gleaner Cholesterol-lowering drugs no help in fighting cancer: review - Jan 3, 2006 Researchers in the US analyzed the results of 26 studies involving more than 73000 people taking the statins such as simivastatin (Zocor) and pravachol ... CBC.ca Celera Publishes Three Papers Linking a Heart Disease Variant and … - Jan 22, 2008 Celera says that it will publish three papers in the January 29 edition of the Journal of the American College of Cardiology detailing how a variant of the ... Genetic Engineering News - Genetic Engineering News (press release) FDA ADVISERS REJECT MERCK'S REQUEST FOR OTC MEVACOR - Jan 14, 2005 A joint panel of FDA advisers has recommended the agency not approve Merck's application to convert its cholesterol-lowering statin Mevacor from ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones FDA grants Teva generic Pravachol marketing approval - Apr 28, 2006 Just days after Bristol-Myers Squibb's patent for its cholesterol-lowering blockbuster Pravachol (pravastatin sodium tablets) expired on April 20, ... Medical Marketing & Media - Medical Marketing and Media Crestor Bests Pravachol for Elevated Lipids - Oct 27, 2007 By David Evans and Tim Horn. Crestor (rosuvastatin) is superior to Pravachol (pravastatin) in HIV-positive people on antiretroviral therapy who experience ... AIDSmeds.com HIV/AIDS Treatment News Competitors by Product Report - Oct 4, 2008 Healthcare. Biopharmaceuticals. Allergies. Systemic. Anaphylactic Shock. Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists ... $75.00 - Revere - Alacra Store Bentley announces score of Spanish generics approvals - Feb 28, 2006 Bentley Pharmaceuticals saw its shares rise by around 6% after announcing that it had received 12 marketing approvals in Spain for its generic versions of ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Federal Judge Blasts FDA Over Pravachol Exclusivity Ruling - Nov 2, 2005 An FDA decision that wiped out Teva Pharmaceutical's market exclusivity for a generic version of Bristol-Myers Squibb's (BMS) lucrative cholesterol-lowering ... Pay-Per-View - Generic Line - Factiva, from Dow Jones Generics fuel rise in statin use.(Generic Drugs) - Mar 19, 2007 WASHINGTON--Prescriptions for cholesterol-lowering drugs are rising because of the increasing availability of generics, according to a recent analysis by ... Free with registration - Chain Drug Review - AccessMyLibrary.com Sales rise 8% in Europe - Apr 20, 2006 POSITIVE SHOW: Mr Malvinder Mohan Singh, CEO and Managing Director of Ranbaxy Laboratories, with Mr Ram S. Ramasundar, CFO & President, ... The Hindu The McManus family of Chicago -- with a daughter plus twins and... - Nov 13, 2007 Then in quick succession they had a daughter, followed by twins, followed by triplets. At one point, they were changing 400 diapers a week. ... $2.95 - Chicago Sun-Times - NewsBank Insurer urges pill-splitting to ease swollen expenses - Jun 4, 2006 QUALITIES OF LIFE: HEALTH. In another push following an initial effort made last fall, the second-largest health insurer in Illinois is encouraging its ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Medical News: Preventive Care - Oct 6, 2005 By Peggy Peck, Senior Editor, MedPage Today. BALTIMORE - The new Medicare prescription-drug coverage plan doesn't cover all of the expenses for all of the ... MedPage Today Statin drugs: Benefits versus risks - Aug 26, 2008 By Judy Rupp commentary. If you're one of the 12 million Americans now taking a cholesterol-lowering statin drug, you know the benefits. ... Enid News & Eagle Prevention of Prevention - Magazine renewed subscription without her ... - Nov 13, 2007 I'm getting billed by a collection agency, even though I asked them to stop. I find it hard enough to pay my legitimate bills, let alone a bogus bill. ... $2.95 - Chicago Sun-Times - NewsBank Statins Could Still Go OTC, Despite Recent Setback - Feb 21, 2005 Though the Food and Drug Administration is likely to reject Merck & Company Inc.'s request to offer an over-the-counter version of its prescription ... ICIS Article: Drug makers ask judge to stop generic pill - The Record... - Aug 19, 2006 Drug makers ask judge to stop generic pill ... find The Record (Bergen County, NJ) articles. DUNSTAN PRIAL, STAFF WRITER The Record (Bergen County, ... Pay-Per-View - The Record - HighBeam Research Single, double, triple; The McManus family of Chicago -- with a... - Nov 13, 2007 Single, double, triple; The McManus family of Chicago -- with a daughter plus twins and triplets -- illustrates a growing trend, doctors say, ... Pay-Per-View - Chicago Sun-Times - HighBeam Research Statin Use Linked to Reduced Risk of Colorectal Cancer - May 25, 2005 By Peggy Peck, Senior Editor, MedPage Today. ANN ARBOR, Mich., May 25-People taking statins -- but not other lipid lowering drugs -- reduced their risk of ... MedPage Today KAI, BMS Join Forces in $227M Heart Drug Deal - May 13, 2008 ...(BioWorld Today Via Acquire Media NewsEdge) KAI Pharmaceuticals Inc. is partnering with Bristol-Myers Squibb Co. to develop and commercialize KAI's heart ... TMC Net Telomere Length Linked to Risk of Coronary Heart Disease - Jan 12, 2007 By Judith Groch, Senior Writer, MedPage Today. LEICESTER, England, Jan. 12 -- One of the apparently myriad benefits of statins in coronary artery disease ... MedPage Today FDA Approves Teva's Pravachol After Court Dissolves Stay on … - Apr 26, 2006 The FDA has granted final approval to Teva Pharmaceutical to market its version of Bristol-Myers Squibb's cholesterol drug Pravachol, after a federal ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones Merck Strengthens Its Prescription Medicines Portfolio in Latin... - Jun 10, 2008 Merck KGaA announced today that its Merck Serono division signed a distribution agreement with Bristol-Myers Squibb Company (NYSE: BMY) for a portfolio of ... Lifescience-online PRECONFERENCE REPORT: American College of Cardiology - Mar 3, 2005 By Peggy Peck, Senior Editor, MedPage Today. The American College of Cardiology (ACC) Scientific Session 2005 opens Sunday with the ACC Interventional ... MedPage Today Favorable outlook for generic APIs a spate of drugs are scheduled to ... - Aug 1, 2007 The near and long-term outlook for generic drugs is robust, creating both opportunities and challenges for generic drug manufacturers and suppliers of ... Free with registration - Pharmaceutical Technology - AccessMyLibrary.com Dr Reddys Laboratories Ltd acquires Dowpharma-small molecules from … - Apr 30, 2008 UK - Dr Reddys Laboratories Ltd acquired the small molecules business of Dowpharma, a Cambridge-based is a biotechnology company. Terms were not disclosed. Pay-Per-View - deals - Alacra Store FDA CAPSULES - May 9, 2006 GENERIC VERSION OF CHOLESTEROL DRUG PRAVACHOL APPROVED. The Food and Drug Administration has approved the first generic version of the cholesterol-lowering ... Pay-Per-View - Newsday - ProQuest Archiver Pipeline match for possible Bristol-Myers Squibb and Sanofi-Aventis … - Jan 31, 2007 By Mike Nagle, 31-Jan-2007. Bristol-Myers Squibb and Sanofi-Aventis could join forces to become the world's largest pharmaceutical company, according to ... DrugResearcher.com FDA panels vote against OTC status for statin drug - Feb 7, 2005 Concern that patients would be taking the medication inappropriately led to a decision to continue to have physicians supervise patients who could benefit ... American Medical News STATINS' ANTI-CANCER BENEFIT DISCOUNTED - Jan 15, 2006 ...[Carolyn Runowicz] said a few of the studies reviewed by [C. Michael White] and his colleagues seemed to suggest statins could provide some protection from ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver Merger and Acquisition Scenario - Jan 26, 2008 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 22.97, Market Cap.:, 45.45B. Target:, Adams Respiratory Therapeutics, Inc. (ARXT), Last Price:, 59.99 ... $250.00 - Revere Reports - Revere Critics say generics thwarted.(POLICY & PRACTICE)(Brief article) - Jun 1, 2006 At least 14 brand name drugs are due to go off-patent in the next 5 years, representing $23 billion in potential savings to Medicare Part D, ... Free with registration - Internal Medicine News - AccessMyLibrary.com Early Statins Disappointing After Acute Coronary Syndrome - May 2, 2006 By Peggy Peck, Managing Editor, MedPage Today. BASEL, Switzerland, May 2-Early statin therapy following acute coronary syndrome does not reduce the risk of ... MedPage Today DSM accelerates anti-infective activity - Oct 19, 2006 By Kirsty Barnes, 19-Oct-2006. Using a processing technique described as "revolutionary," DSM is accelerating its activity in the anti-infective arena and ... In-PharmaTechnologist.com Antidyslipidemics: Market set for contraction as generics hit hard. - Oct 3, 2006 London - At the end of 2005 the antidyslipidemics market was worth a staggering $27 billion*, with the statin class commanding over 85% of the market. ... Free with registration - M2 Presswire - AccessMyLibrary.com Iron deficiency not the only cause - Jul 3, 2005 Dear Dr. Donohue: More than a year ago I became anemic. My doctor has me on three iron-tablets a day. They give me diarrhea, and it has been difficult to ... Victoria Advocate - Google News Archive Merger and Acquisition Scenario - Jan 12, 2008 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 26.48, Market Cap.:, 52.39B. Target:, Amgen, Inc. (AMGN), Last Price:, 47.62, Market Cap.:, 51.79B ... $250.00 - Revere Reports - Revere Suboptimal Statin Use Seen Common and Harmful - Dec 7, 2006 By Crystal Phend, Staff Writer, MedPage Today. UTRECHT, The Netherlands, Dec. 7 -- Statins are being underdosed by physicians and underused by patients, ... MedPage Today Statins Effective in Primary Prevention of Cardiovascular Disease - Nov 28, 2006 By Judith Groch, Senior Writer, MedPage Today. BOSTON, Nov. 28 -- Statins are effective in primary prevention for patients free of cardiovascular disease, ... MedPage Today Patent Expiries of Merck's Zocor and Bristol-Myers Squibb's Pravachol... - Oct 5, 2005 WALTHAM, Mass., Oct. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and ... Free with registration - PR Newswire - AccessMyLibrary.com Merger and Acquisition Scenario - Jan 26, 2008 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 22.97, Market Cap.:, 45.45B. Target:, MGi Pharma, Inc. (MOGN), Last Price:, 40.99, Market Cap.:, 3.30B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 19, 2007 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 30.45, Market Cap.:, 59.93B. Target:, Merck Serono S.A. (ADR) (SRA), Last Price:, 22.72, Market Cap. ... $250.00 - Revere Reports - Revere Statin-Breast Cancer Risk Ruled out - May 17, 2006 By Michael Smith, MedPage Today Staff Writer. PITTSBURGH, May 17 — There's no increased risk of breast cancer for postmenopausal women who take statins, ... MedPage Today APPEALS COURT AFFIRMS RULING DENYING APOTEX'S REQUEST … - Jun 8, 2006 A federal appeals court ruling in a case pitting drugmakers Apotex and Teva Pharmaceutical against one another could make it harder for generic firms to ... Pay-Per-View - FDAnews Drug Daily Bulletin - Factiva, from Dow Jones Medical test results sometimes biased - Nonprofit researchers give... - May 18, 2006 ...• When a drug company or device-maker funds a clinical trial for a new cardiovascular treatment, the outcome is likely to favor the new treatment, ... Pay-Per-View - Dayton Daily News - NewsBank Drug incompatibility is irksome I . - Jul 28, 2006 Dear Dr. Donohue: My fasting blood work showed high cholesterol, triglycerides and cholesterol. I had been taking Tricor and Pravachol as well as estrogen. ... Bangor Daily News - Google News Archive Benefit Seen for Intensive Statins in Acute Coronary Syndrome - Sep 26, 2006 By Crystal Phend, Staff Writer, MedPage Today. WASHINGTON, Sept. 26 -- Accentuate the statins within two weeks of hospitalization for acute coronary ... MedPage Today Daiichi Sankyo, Inc. Data show addition of a bile acid sequestrant to... - May 15, 2006 2006 MAY 15 - (NewsRx.com) -- Data published in the April 15 issue of the American Journal of Cardiology demonstrated that adding WelChol (colesevelam ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Merger and Acquisition Scenario - Jan 27, 2007 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 26.21, Market Cap.:, 51.55B. Target:, ICOS Corporation (ICOS), Last Price:, 33.98, Market Cap.:, 2.23B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 21.64, Market Cap.:, 42.56B. Target:, Protherics PLC (ADR) (PTIL), Last Price:, 14.24, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 25.61, Market Cap.:, 50.37B. Target:, KOS Pharmaceuticals, Inc. (KOSP), Last Price:, 78.00, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 21.94, Market Cap.:, 43.43B. Target:, Millennium Pharmaceuticals, Inc. (MLNM), Last Price:, 24.97 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 5, 2008 Buyer:, Merck & Co., Inc. (MRK), Last Price:, 40.00, Market Cap.:, 87.37B. Target:, Bristol Myers Squibb Co. (BMY), Last Price:, 22.19, Market Cap.:, 43.92B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jun 16, 2007 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 30.76, Market Cap.:, 60.54B. Target:, MedImmune, Inc. (MEDI), Last Price:, 57.94, Market Cap.:, 13.84B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 7, 2007 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 27.82, Market Cap.:, 54.75B. Target:, New River Pharmaceuticals, Inc. (NRPH), Last Price:, 63.73 ... $250.00 - Revere Reports - Revere Critics say generics thwarted.(Policy & Practice) | Article from Skin... - Jun 1, 2006 Critics say generics thwarted.(Policy & Practice) ... find Skin & Allergy News articles. At least 14 brand name drugs are due to go off patent in the next 5 ... Pay-Per-View - Skin & Allergy News - HighBeam Research Merger and Acquisition Scenario - Dec 16, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 25.61, Market Cap.:, 50.37B. Target:, Altana AG (ADR) (AAA), Last Price:, 60.77, Market Cap.:, 8.25B ... $250.00 - Revere Reports - Revere Treatment target needed for HDL cholesterol, expert says.(Cardiovascul... - Sep 15, 2005 Treatment target needed for HDL cholesterol, expert says.(Cardiovascular Medicine)(high-density lipoprotein cholesterol ) ... find Family Practice News ... Pay-Per-View - Family Practice News - HighBeam Research Merger and Acquisition Scenario - Mar 8, 2008 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 21.88, Market Cap.:, 43.31B. Target:, Pharmion Corporation (PHRM), Last Price:, 72.32, Market Cap. ... $250.00 - Revere Reports - Revere Critics say generics thwarted.(POLICY & PRACTICE)(Brief article) |... - Jun 1, 2006 Zocor (simvastatin), Proscar (finasteride), and Pravachol (pravastatin). The Food and Drug Administration just approved a generic pravastatin. ... Pay-Per-View - Internal Medicine News - HighBeam Research Japan stock market week to Feb 20, 2006. - Feb 27, 2006 Tokyo saw another pullback in the week ended February 20, following seesaw movements. The Nikkei 225 fell 2.8%, to close at the 15400 level, while the Topix ... $4.95 - Pharma Marketletter - ECNext The FDA.(Pipeline) | Article from Medical Marketing & Media |... - Dec 1, 2006 The FDA.(Pipeline) ... find Medical Marketing & Media articles. The FDA approved the first generic version of Galderma's MetroGelVaginal (metronidazole), ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Statins provide benefits after use stopped. - Oct 22, 2007 The results of a survey published in New England Journal of Medicine indicate that cholesterol-lowering statins help prevent heart attacks for at least a ... $4.95 - Pharma Marketletter - ECNext Merger and Acquisition Scenario - Mar 22, 2008 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 21.46, Market Cap.:, 42.48B. Target:, Axcan Pharma Inc. (USA) (AXCA), Last Price:, 23.34, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 19, 2006 Buyer:, Johnson & Johnson (JNJ), Last Price:, 64.42, Market Cap.:, 188.43B. Target:, Bristol Myers Squibb Co. (BMY), Last Price:, 21.64, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 15, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 24.04, Market Cap.:, 47.21B. Target:, Chiron Corporation (CHIR), Last Price:, 47.94, Market Cap. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 4, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 24.53, Market Cap.:, 48.24B. Target:, Andrx Corporation (ADRX), Last Price:, 25.00, Market Cap.:, 1.85B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 13, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 24.29, Market Cap.:, 47.76B. Target:, Neurocrine Biosciences, Inc. (NBIX), Last Price:, 52.74 ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 11, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 22.91, Market Cap.:, 44.82B. Target:, Acambis plc (ADR) (ACAM), Last Price:, 7.21, Market Cap.:, 3.87B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 Buyer:, Bristol Myers Squibb Co. (BMY), Last Price:, 24.47, Market Cap.:, 48.13B. Target:, Schering AG (ADR) (SHR), Last Price:, 120.31, Market Cap. ... $250.00 - Revere Reports - Revere The highs and lows in cholesterol: cholesterol drug marketers still... - Mar 1, 2007 Every cholesterol drug marketer remembers where they were when the titanic news first broke of the sinking of Pfizer's torcetrapib heart drug. ... Free with registration - Medical Marketing & Media - AccessMyLibrary.com Meta-analysis in The Lancet recommends statins for all diabetics, … - Jan 21, 2008 A meta-analysis published in the January 12 issue of the presitigous journal, The Lancet, suggests that diabetics should receive cholesterol-lowerings drugs ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Scientists uncover gene mutation key to cholesterol control - Apr 20, 2006 By Wai Lang Chu, 20-Apr-2006. Researchers think they have found a gene, which when disrupted interferes with the ability to absorb lipids through the ... DrugResearcher.com Merck Serono firmó acuerdo para distribuirle a Bristol-Myers Squibb … - Jun 12, 2008 Según el acuerdo, Merck Serono (división de Merck) adquirirá los derechos para comercializar y distribuir cerca de 30 medicamentos de prescripción médica, ... Portafolio New Survey Reveals Many Adults With High Cholesterol Fail to Take … - Sep 4, 2007 PARSIPPANY, NJ--(Marketwire - September 4, 2007) - A recent survey of US adults with high cholesterol* shows that in spite of concerns about the serious ... marketwire.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |